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1. Introduction 
The human immunodeficiency virus type 1 (HIV-1) pandemic has claimed over 20 million 
lives, with 38.6 million people worldwide currently infected (2009 AIDS Epidemic Update 
by UNAIDS/WHO, www.unaids.org), and will continue to contribute to human morbidity 
and mortality. The number of people living with HIV-1 continues to rise worldwide because 
of high rates of new infections and the success of antiretroviral therapy (ART, also known as 
the highly active antiretroviral therapy or HAART). HIV-1 infection results in a variety of 
syndromes involving both the central and peripheral nervous systems. HIV-1 invades the 
central nervous system (CNS) early during the course of infection and persists thereafter in 
the absence of treatment. HIV-1 infection of the CNS is often associated with neurological 
complications including HIV-1-associated severe and mild neurologic disorders. Prior to 
HAART, neurologic disorders were the first manifestation of symptomatic HIV-1 infection, 
affecting roughly 10% – 20% of patients and up to 60% of patients in the advanced stages of 
acquired immunodeficiency syndrome (AIDS)1. HIV-1 infection is also associated with 
neuropathic pain, which is caused by peripheral nervous system injury. The vast majority 
(up to 90%) of individuals infected with HIV-1 have pain syndromes that significantly 
impact their well-being2-13. A variety of pain syndromes including peripheral neuropathies, 
headache, oral and pharyngeal pain, abdominal and chest pain, arthralgias and myalgias as 
well as pain related to HIV-1/AIDS-associated malignancies such as Kaposi’s sarcoma14,15. 
Pain occurs at all stages of HIV-1 infection, although its severity and frequency are 
correlated with disease progression2,16. In the era of HAART, patients infected with HIV-1 
live longer, and management of their symptoms including pain has emerged as a top 
priority for HIV-1 clinical and translational research. 
Uniquely, neuronal injury, cell loss and dysfunction during HIV-1 infection appear to occur 
through soluble neurotoxins rather than productive virus infection, because there is no 
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evidence that HIV-1 directly infects neurons. Apoptosis, an active process of cell death 
characterized by cell shrinkage, chromatin aggregation with genomic fragmentation and 
nuclear pyknosis, appears to be an important feature of HIV-1-associated central neurological 
dysfunction and peripheral neuropathy. Apoptotic neurons have been observed in the CNS of 
HIV-1-infected individuals, and are more abundant in HIV-1 patients with peripheral 
neuropathy. Herein, we review the role of neuronal apoptosis in HIV-1-associated 
neurological disorders, focusing on HIV-1-associated CNS manifestations and sensory 
neuropathic pain. This review also summarizes the current data supporting both the direct 
and indirect mechanisms by which neuronal apoptosis may occur during HIV-1 infection. 
Finally, we discuss recent and past approaches for the prevention and treatment of HIV-1-
associated neurological disorders by targeting specific neurotoxic signaling pathways.  
2. Overview of HIV-1-associated neurological disorders 
Neurologic disorders are among the most frequent and devastating complications of HIV-1 
infection. Prior to HAART, neurologic disorders were the first manifestation of symptomatic 
HIV-1 infection, affecting roughly 10% – 20% of patients and up to 60% of patients in the 
advanced stages of HIV-1/AIDS1. The incidence of subclinical neurologic disease is much 
higher. Autopsy studies of AIDS patients have demonstrated pathologic abnormalities of 
the nervous system in 75 - 90% of cases17,18. Neurologic disorders continue to be prevalent in 
the era of HAART. HAART has reduced the incidence of severe forms of AIDS-associated 
neurologic disorders such as HIV-1-associated dementia (HAD), but with longer life span, 
the prevalence of milder forms of neurologic manifestations such as HIV-1-associated 
neurocognitive disorder (HAND) appears to be increasing19,20. In resource-rich settings such 
as the United States and the European Union, where antiretroviral therapy is relatively 
available, peripheral neuropathy and HIV-1-associated cognitive dysfunction (including 
HAD) account for the greatest proportion of neurologic disease burden21,22. In resource-poor 
settings such as developing countries, opportunistic infections of CNS account for most of 
the reported neurologic morbidity and mortality in AIDS patients23. Fulminant bacterial 
meningitis, cryptococcal meningitis, neurotuberculosis, neurosyphilis, and toxoplasmosis 
are common among HIV-1-infected individuals in Asia and Africa23. 
The neuropathic syndromes associated with HIV-1 infection are diverse and include both 
the somatic and autonomic nervous systems. The primary pathological abnormality may be 
demyelination, both acute and chronic, or axonal degeneration. Either single or multiple 
nerves may be involved leading to mono- or polyneuropathy. HIV-1 invades the CNS early 
in the infectious course, and eventually causes mild or severe forms of HIV-1-associated 
neurologic manifestations24. Severe manifestations include HIV-1-assocated dementia 
complex (HAD, HIV-1-encephalopathy, and subacute encephalitis) and HIV-1-associated 
myelopathy, whereas mild manifestations include HIV-1-associated neurocognitive/motor 
disorders and HIV-1-associated neurobehavioral abnormalities (Table 1)25. HIV-1 also affects 
the peripheral nervous system (PNS) and PNS damage can be assessed by 
electroneurographic examinations quantifying nerve conduction velocity (NCV) and action 
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potential amplitudes. Defined disorders of the PNS comprise the HIV-1-associated Guillain-
Barré syndrome and sensory polyneuropathy (Table 1)26. 
 
Table 1. HIV-1-associated CNS and PNS disorders 
HAD: HIV-1-associated dementia; HIVE: HIV-1-associated encephalopathy; HIVM: HIV-1-associated 
myelopathy. 
3. Neuronal apoptosis in the central nervous system in HIV-1 infection  
Apoptosis of neurons and non-neuronal cells has been demonstrated in the brain of HAD 
patients27. Petito and Roberts reported that neuronal and astrocytic death in HIV-1 infection 
occurred by apoptosis27. They identified apoptotic neurons, astocytes, and multinucleated 
giant cells in the brain of adults with HIV-1-associated encephalopathy (HIVE) using a 
combined approach of in situ end labeling (ISEL) and immunohistochemistry27. Neuronal 
apoptosis occurs not only in HIV-1-infected adults but also in infected children. Using an in 
situ technique, Gelbard et al found that newly cleaved 3'-OH ends of DNA, a marker for 
apoptosis, in the brain of children with HIVE28. They demonstrated the presence of 
apoptotic neurons in cerebral cortex and basal ganglia of children that had HIVE with 
progressive encephalopathy28. In addition, association of the localization of apoptotic 
neurons with perivascular inflammatory cell infiltrates containing HIV-1 infected 
macrophages and multinucleated giant cells was observed28. Adle-Biassette et al found 
apoptotic perivascular cells in the brain of adults with HIVE29. Neuronal apoptosis was 
more severe in atrophic brains, and did not directly correlate with productive HIV-1 
infection, suggesting that an indirect mechanism of neuronal damage exists. Shi et al 
demonstrated neuronal apoptosis in brain tissue from AIDS patients and in HIV-1-infected 
primary human fetal brain cultures30. HIV-1 infection of primary brain cultures induced 
apoptosis in neurons and astrocytes in vitro as determined by terminal deoxynucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL) and propidium iodide (PI) staining 
and by electron microscopy30. Apoptosis was not significantly induced until 1 - 2 weeks after 
the time of peak virus production, suggesting that apoptosis of neurons and non-neuronal 
cells in HIV-1 infection is triggered by soluble factors rather than by direct viral infection30. 
An et al used ISEL technique to examine neuronal apoptosis in the brains of AIDS and pre-
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AIDS patients31,32. The presence of apoptotic cells in the brains of HIV-1-positive pre-AIDS 
individuals was observed, although the frequency was lower than that in the brain of AIDS 
patients. These data suggest that brain damage already occurs during the early stages of 
HIV-1 infection31,32. 
Apoptotic neurons are found in several regions of the brain of adults with HIVE including 
the frontal and temporal cortex, basal ganglia and brain stem27-32. The basal ganglia 
apoptotic neurons were found to be more abundant in the vicinity of activated microglia 
that had higher HIV-1 copies as determined by measuring HIV-1 core proteins31,32. Within 
the cerebral cortex, the extent of neuronal apoptosis correlated with cerebral atrophy 
patients31,32. In addition, apoptotic neurons in the basal ganglia and cerebral cortex of 
children with HIVE were detected in the vicinity of perivascular inflammatory cell 
infiltrates containing HIV-1- infected multinucleated giant cells and macrophages26. 
 
Figure 1. Neuronal apoptosis in the central nervous system in HIV-1 infection. 
Monocytes/macrophages (M/MΦ) play a crucial role in HIV-1-associated neurologic disorders. They are 
among the first cells infected by HIV-1, which then forms a reservoir of HIV-1 in infected individuals. 
HIV-1-infected monocytes/macrophages serve as a means (Trojan horse) of spreading the virus to other 
tissues such as the brain. HIV-1 gains entry into the brain within macrophages that efficiently produce 
new virions. These virions infect microglia, astrocytes, endothelial cells, and multinucleated giant cells 
in the brain. Virions and viral proteins, and the neurotoxic factors released from HIV-1-infected cells 
induce apoptosis of neurons. The disruption of glutamate homeostasis induces neuronal excitotoxicity, 
resulting in neuronal cell death.  
In addition to apoptotic neurons, apoptosis of other CNS cell types in the brain of HAD 
patients has also been reported. Apoptotic astrocytes were detected and found to be more 
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common in the brain of HAD patients compared to non-demented HIV-1/AIDS patients27-32. In 
addition, greater numbers of apoptotic astrocytes were detected in the brains of AIDS patients 
with rapidly progressing dementia compared to slow progressors28,29. Astrocytes are the most 
abundant cells of the human brain, and perform many functions including biophysical 
support of endothelial cells that form the blood–brain barrier (BBB), provision of nutrients to 
the nervous tissue, maintenance of extracellular ion balance, and a role in the repair and 
scarring process of the brain and spinal cord following traumatic injuries. HIV-1-mediated loss 
of astrocytes impairs maintenance of the BBB and alters the composition of the extracellular 
environment, resulting in increased BBB permeability. These findings suggest that astrocyte 
cell loss plays a critical role in the neuropathogenesis of HAD (Figure 1). Table 2 summarizes 
the studies in vivo and in vitro on neuronal apoptosis in HIV-1 infection.  
 
Table 2. Summary of in vitro and in vivo studies on neuronal apaoptsois in HIV-1 infection 
4. Neuronal apoptosis is associated with pain in HIV-1-infected patients.  
 The vast majority (up to 90%) of individuals living with HIV-1 have pain syndromes that 
significantly impact their well-being2-13. Pain occurs at all stages of HIV-1 infection, although 
its severity and frequency are correlated with disease progression2,16. In the era of HAART, 
patients infected with HIV-1 live longer, and management of their symptoms including pain 
is emerging as a top priority for HIV-1 clinical and translational research. However, pain is 
often under-assessed and undertreated in people with HIV-1/AIDS, and little progress has 
been made in understanding the underlying mechanisms that are key for pain management 
and improvement of quality of life.  
The pain in HIV-1-infected patients is believed to result from (1) direct neurotoxic effects of 
viral components on neurons in both central and peripheral nervous systems, (2) immune 
dysregulation leading to inflammatory changes, opportunistic infections and/or tumors, and 
(3) the adverse effects related to antiviral drugs2,3,33. Viral proteins are directly involved in 
neuronal damage and death. HIV-1 encodes a total of nine viral proteins including three 
structural proteins (Env, Pol, and Gag), two essential regulatory proteins (Tat and Rev), and 
four accessory proteins (Vif, Vpr, Vpu, and Nef). These viral proteins have been extensively 
studied for their role in HIV-1-associated CNS neuropathy. To date, five of these proteins 
including Env, Tat, Vpr, Nef, and Rev have been identified as potent neurotoxic viral 
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proteins in that they directly induce neuronal cell death (Figure 2). These proteins are 
implicated in HIV-1-associated CNS pathologies such as mild to severe cognitive 
impairments and encephalitis34-43. Recent studies have shown that Env and Vpr exert 
neurotoxic activities on peripheral sensory neurons (pain-sensing neurons). Injection of Env 
into the spinal intrathecal space of rats causes marked pain-like effects44-48, and Vpr 
enhances excitability of dorsal root ganglion (DRG) neurons49. These results suggest that 
HIV-1 neurotoxic proteins have direct effects on peripheral nerves, and may be causative 
factors in the generation of neuropathic pain in HIV-1-infected individuals.  
 
Figure 2. HIV-1 genome and viral proteins. HIV-1 is composed of two copies of single-stranded RNA 
genome with approximately 9700 bp in length. HIV-1 genome encodes a total of nine viral proteins 
including three structural proteins (Env, Pol, and Gag in open boxes), two essential regulatory proteins 
(Tat and Rev in black boxes), and four accessory proteins (Vif, Vpr, Vpu, and Nef in gray boxes). Genes 
encoding HIV-1 proteins with know neurotoxicity are given in bold.  
HIV-1 Env gene encodes a 160-kDa envelope glycoprotein (gp160) precursor, which is 
proteolytically cleaved into the exterior (gp120) and transmembrane (gp41) glycoproteins. 
The gp120 remains associated with the mature envelope glycoprotein complex through a 
non-covalent interaction with the gp41 ectodomain. Three exterior gp120 glycoproteins 
and three transmembrane gp41 proteins are assembled as a trimer by non-covalent 
interactions. The gp120 has been shown to directly interact with neurons, leading to 
neuronal apoptosis. In vivo experiments have shown that subcutaneous injection of 
purified recombinant gp120 in neonatal rats causes dystrophic changes in pyramidal 
neurons of cerebral cortex accompanied by abnormalities of developmental behaviors50. 
Toggas et al generated transgenic mice expressing gp120 mRNA in astrocytes and found a 
spectrum of neuronal and glial changes resembling abnormalities in brains of HIV-1-
infected individuals51. The severity of brain damage correlated positively with the brain 
level of gp120 expression51. These results provide in vivo evidence that gp120 plays a key 
role in HIV-1-associated nervous system impairment. Damage of neurons has also been 
reported in transgenic mice expressing the entire HIV-1 genome52, Tat53, or Vpr54. 
Transgenic mice expressing Nef55,56 primarily showed severe impairment of thymocyte 
development and peripheral T-cell function by a CD4-independent mechanism. Nef 
expression in these mice also indirectly contributes to HIV-1-associated neuropathy by 
enhancing protein expression of other HIV-1 genes and altering cellular maturation in 
vivo57. In vitro exposure to HIV-1 proteins including gp160, gp120, gp41, Tat, Nef, Rev, and 
Vpr has been reported to initiate neuronal damage58-62.  
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Dorsal root ganglion (DRG) neurons have central terminals in the spinal cord dorsal horn 
and peripheral terminals in skin, muscle and other peripheral tissues. These DRG neurons 
transmit and relay pain-related signals and temperature sensation from peripheral tissues to 
the spinal cord and brain. Neurotoxins and inflammatory molecules cause hyperexcitability 
of primary DRG neurons leading to spontaneous or persistent firing. These agents also 
induce apoptosis of DRG neurons, resulting in permanent neuron damage, death, and nerve 
lesions. It is well established that peripheral sensitization of primary DRG neurons is the key 
event in the onset of chronic pain conditions 63. Peripheral sensitization is defined as the 
enhancement of a baseline response, such as action potential (AP) firing, after exposure to a 
defined mediator 63. For example, exposure to the pro-inflammatory prostaglandin E2 
(PGE2), increases the number of APs evoked by an excitatory stimulus by about three-fold 
compared to the control, thus the neuronal output is intensified by PGE2 64,65. This increased 
firing is believed to be critical in the enhanced perception of pain sensation for both 
inflammatory and neuropathic conditions 64,65. Our group has recently explored the direct 
effects of HIV-1 Tat protein on excitability of rat primary DRG neurons62. We demonstrated 
that HIV-1 Tat triggered a rapid and sustained enhancement of the excitability of small-
diameter rat primary DRG neurons, which was accompanied by marked reductions in the 
rheobase and resting membrane potential (RMP), and an increase in the resistance at 
threshold (RTh). Such Tat-induced DRG hyperexcitability may be a consequence of the 
inhibition of cyclin-dependent kinase 5 (Cdk5) activity. Tat rapidly inhibited Cdk5 kinase 
activity and mRNA production, and roscovitine, a well-known Cdk5 inhibitor, induced a 
very similar pattern of DRG hyperexcitability. Indeed, pre-application of Tat prevented 
roscovitine from having additional effects on the RMP and action potentials (APs) of DRGs. 
However, Tat-mediated actions on the rheobase and RTh were accelerated by roscovitine. 
These results suggest that Tat-mediated changes in DRG excitability are partly facilitated by 
Cdk5 inhibition. In addition, Cdk5 is most abundant in DRG neurons and participates in the 
regulation of pain signaling. We also demonstrated that HIV-1 Tat markedly induced 
apoptosis of primary DRG neurons after exposure for longer than 48 h. Together, our work 
indicates that HIV-1 proteins are capable of producing pain signaling through direct actions 
on excitability and survival of sensory neurons. 
However, we still do not know: (1) whether all five HIV-1 neurotoxic proteins induce pain-
related signaling, (2) what is their rank order for induction of pain-related signaling, (3) 
whether these neurotoxic proteins exert synergistic effects on pain-related signaling, and (4) 
the molecular mechanisms by which HIV-1 neurotoxic proteins exert neuropathogenic 
effects on sensory neurons. Clarification of these issues will have potentially important 
implications for developing therapeutic strategies to prevent or treat HIV-1-assciated pain. 
For example, early initiation of HAART and/or neutralization of HIV-1 protein neurotoxicity 
may significantly prevent or delay HIV-1-associated pain. 
5. Mechanisms of neuronal apoptosis induced by HIV-1 infection 
There are two main apoptotic pathways: the extrinsic or death receptor pathway and the 
intrinsic or mitochondrial pathway66,67. There is an additional pathway that involves T-cell 
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mediated cytotoxicity and perforin-granzyme-dependent killing of the cell by inducing 
apoptosis via either granzyme B or granzyme A67. The extrinsic and intrinsic pathways are 
initiated by caspase-3 activation induced by proteolytic cleavage and results in DNA 
fragmentation, degradation of cytoskeletal and nuclear proteins, formation of apoptotic 
bodies, expression of ligands for phagocytic cell receptors and finally uptake by phagocytic 
cells, whereas the granzyme pathway activates a parallel, caspase-independent cell death 
pathway via single stranded DNA damage. All of these three pathways may be involved in 
neuronal apoptosis in HIV-1 infection.  
5.1. Extrinsic pathway  
Several factors including neurotoxins such as tumor necrosis factor alpha (TNF-α) secreted 
by HIV-1–infected macrophages and microglia, and soluble forms of the HIV-1 gp120 and 
Tat proteins have been reported to mediate HIV-1-induced neuronal injury30. TNF-α is 
elevated in the serum, cerebrospinal fluid (CSF), and brain of AIDS patients. The elevated 
TNF-α levels have been shown to correlate with clinical dementia68. The binding of TNF-α 
to TNF-α receptor-1 (TNFR1) on the surface of neurons activates TNFR1-associated death 
domain protein (TRADD), which in turn interacts with Fas-associated death domain protein 
(FADD) to induce apoptosis of neurons69. However, TNF-α and TNF-beta (TNF-β) have also 
been shown in certain circumstances to be neuroprotective. TNF-α and TNF-β protect 
cultured embryonic rat hippocampal, septal, and cortical neurons against glucose 
deprivation-induced injury and excitatory amino acid toxicity70. TNF-α induces the 
expression of the chemokine CX3CL1 in astrocytes71, which in turn protects neurons from 
HIV-1 gp120-mediated toxicity72. TNF-α protective or destructive effects on neuronal 
survival depend on the timing, duration, and concomitant expression of other elements.  
The TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, is 
also involved in neuronal apoptosis73. TRAIL is a type II integral membrane protein and 
expressed by multiple cell types73. TRAIL protein levels were increased in human monocyte-
derived macrophages after HIV-1 infection and immune activation73. In the brain of HIVE 
patients, TRAIL-expressing macrophages were found in association with active caspase-3 
positive neurons73. In vitro studies have shown that TRAIL induces a dose-dependent effect 
on neuronal apoptosis73.  
Five HIV-1 proteins including Env, Tat, Vpr, Nef, and Rev, are potent neurotoxic viral 
proteins that cause apoptosis of various neuronal populations in the CNS, resulting in 
pathologies such as cognitive impairment and encephalitis associated with NeuroAIDS 
(Figure 2). HIV-1 gp120 binds with high affinity to CXCR4 expressed on human neurons74, 
resulting in neuronal apoptosis40,75. CXCR4 is a seven transmembrane domain G-protein-
coupled receptor and activation of this receptor via binding of gp120 triggers neuronal 
apoptosis. The exact mechanism underlying gp120-CXCR4-mediated neuronal apoptosis 
remain unclear, but is not related to increases in intracellular calcium (Ca2+) or to induction 
of glutamate uptake by functional glutamate receptors75. Tat appears to exert its neurotoxic 
activity via binding to the N-methyl D-aspartate (NMDA) receptor and the low-density 
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lipoprotein receptor-related protein (LRP)76-79, whereas evidence of Vpr, Nef, or Rev binding 
to surface receptor(s) of neurons is lacking. Binding of HIV-1 Tat to LRP triggers formation 
of a macromolecular complex involving the LRP, NMDA receptors, postsynaptic density 
protein-95 (PSD-95), and neuronal nitric oxide synthase (nNOS) at the neuronal plasma 
membrane. This complex leads to neuronal and astrocyte apoptosis. Blockade of LRP-
mediated Tat uptake, NMDA receptor activation, or nNOS significantly reduces neuronal 
apoptosis, suggesting that formation of this complex is an early step in Tat-mediated 
neuronal apoptosis. CCL2, an inflammatory chemokine, inhibits formation of the complex, 
resulting in protection against Tat-mediated neuronal apoptosis80.  
During HIV-1 infection, multiple viral proteins co-exist in circulation and tissues, and 
synergize with one another to accelerate disease progression. For example, Env and Tat act 
synergistically to cause cell death in CNS neurons81. Vpr and Nef each can induce injury of 
podocytes, and have a synergistic effect on podocyte injury and the subsequent 
development of glomerulosclerosis82. In addition, HIV-1 proteins have synergistic effects 
with inflammatory factors83, methamphetamine84,85, and ethanol86 in acceleratory HIV-1-
associated neurological disorders. Thus, it is possible that the known HIV-1 neurotoxic 
proteins have synergistic effects on neuronal apoptosis.  
5.2. Intrinsic pathway 
The intrinsic (or mitochondrial) pathway of apoptosis is intracellularly initiated in response 
to various types of intracellular signals including growth factor withdrawal, DNA damage, 
unfolding stresses in the endoplasmic reticulum (ER) and death receptor stimulation. The 
intrinsic apoptotic pathway is characterized by permeabilisation of the mitochondria and 
release of cytochrome C (Cyt C) into the cytoplasm. Once it is released, Cyt C binds to the 
cytosolic protein known as apoptotic protease activating factor 1 (Apaf-1) to facilitate the 
formation of the apoptosome, a large multi-protein complex formed in the process of 
apoptosis87,88. Subsequently, the apoptosome binds and activates caspase-9 preproprotein. 
Activated caspase-9 then activates downstream caspases resulting in the activation of 
caspase cascade87,88. 
Studies have shown that HIV-1 Vpr directly interacts with the mitochondrial membrane 
to induce neuronal apoptosis through the intrinsic pathway54. Vpr directly bind to the 
adenine nucleotide translocator (ANT), a component of the mitochondria permeability 
transition pore located on the inner mitochondrial membrane, to trigger a rapid 
dissipation of the mitochondrial transmembrane potential and the mitochondrial release 
of apoptogenic proteins such as Cyt C or apoptosis inducing factor89,90. Vpr induces 
neuronal cell death in vivo in the absence of both profound microglia activation and pro-
inflammatory gene expression54. In addition, Vpr causes neuronal apoptosis independent 
of the presence and function of the p53 tumor suppressor54,91, a transcription factor which 
regulates the expression of several pro-apoptotic proteins such as Bax, Bad, Puma, and 
Bid92. These findings further indicate that Vpr-induced apoptosis is effected via the 
intrinsic pathway. 
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In addition to Vpr, HIV-1 gp120 and Tat also trigger neuronal apoptosis via intrinsic 
pathway93. Both gp120 and Tat enhance p53 expression and phosphorylation, and promote 
BCL-2-associated X protein (Bax) insertion into the mitochondrial membrane. Peripheral 
blood mononuclear cells (PBMCs) and lymph node syncytia from HIV-1 patients show 
accumulation of phosphorylated p5394. Accumulation of p53 protein in neurons of HAD 
patients and in CNS tissues from monkeys with simian immunodeficiency virus (SIV) 
encephalitis (SIVE) has been reported95,96. It is well established that p53 can mediate the 
intrinsic apoptosis pathway94. HIV-1 can establish a productive infection in perivascular 
macrophages and a subset of parenchymal microglia in the brain. These infected cells 
secrete gp120 and other immunomodulatory factors that lead to activation of astrocytes and 
microglia. Accumulation of p53 protein also occurs in neurons and non-neuronal CNS cells, 
which is required in both neurons and microglia for gp120-induced neuronal apoptosis97. 
The Bcl-2 family of proteins plays a key role in the regulation of apoptosis98,99. This gene 
family is comprised of antiapoptotic members including Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl-1, 
and Bcl-B, and proapoptotic members including Bax, Bak, Bad, Bok, Bik, Bid, Bim, Hrk, Blk, 
Bnip3, Noxa, Puma, and Bcl-G100. Both Tat and gp120 promote Bax insertion into the 
mitochondrial membrane and subsequent release of Cyt C93. Such effect of HIV-1 gp120 and 
Tat can be blocked by anti-apoptotic proteins BCL-2/BCL-XL93. In addition, Tat also inhibits 
expression of BCL-2 in neurons, resulting in induction of neuronal apoptosis101. In vitro 
studies have shown that over-expression of Bcl-2 in neuronally differentiated human SK-N-
MC cells protect neurons against Tat-induced apoptosis101. 
Dysregulation of neuronal cell Ca2+ homeostasis plays a central role in both HIV-1 gp120 
and Tat-induced neuronal apoptosis through the intrinsic pathway54,102. Both gp120 and Tat 
disrupt neuronal Ca2+ homeostasis by perturbing Ca2+-regulating systems in the plasma 
membrane and ER. By altering voltage-dependent Ca2+ channels, glutamate receptor 
channels, and membrane transporters, HIV-1 gp120 and Tat promote Ca2+ overload, 
oxyradical production, and mitochondrial dysfunction. Exposure to gp120 induces an 
increased release of arachidonic acid in rat primary neuronal cell culture followed by 
NMDA receptor-mediated neurotoxicity103. The elevated arachidonic acid impairs metabolic 
balance of glutamate in neurons, resulting in lethal levels of Ca2+ influx. As evidence, gp120-
induced neurotoxicity is inhibited by dizocilpine and memantine, two blockers of NMDA 
receptors, and by AP5, a competitive antagonist of the glutamate-binding site on NMDA 
receptors, but not by antagonists of non-NMDA receptors, which are less permeable to 
calcium81,102. Similar to gp120, Tat activates a wide variety of intracellular signals, some of 
which play a critical role in neuronal apoptosis. Tat causes activation of c-Jun N-terminal 
kinases (JNKs), activator protein-1 (AP-1), and phosphatidylinositol 3-kinases (PI3Ks) in a 
time- and dose-dependent manner104,105, leading to increases in activity of the protein kinase 
C (PKC) and mitogen-activated protein (MAP) kinase104. Intact molecules of Tat and peptide 
fragments of Tat, in particular, Tat31–61, increased intracellular Ca2+ in cultured human fetal 
neurons106. The Ca2+ influx contributed to Tat-induced neuron depolarization by activation 
of glutamate receptors106. Tat is also able to increase levels of inositol 1,4,5-triphosphate (IP3) 
that in turn triggers Ca2+ release from IP3-sensitive ER stores in cultured human fetal 
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astrocytes and neurons107. Inhibition of IP3-mediated Ca2+ release from the ER has been 
shown to inhibit Tat-induced neurotoxicity107. Notably, HIV-1 gp120 and Tat have a 
synergistic effect on Ca2+ dysregulation in neurons81. Subtoxic concentrations of gp120 and 
Tat causes prolonged increases in levels of intracellular Ca2+, resulting in neuronal cell 
death. The memantine, a potent NMDA receptor blocker, can completely block the 
neurotoxicity caused by Tat and gp120 applied in combination81. 
Both HIV-1 gp120 and Tat directly stimulate neurons and non-neuronal cells in the brain to 
produce inflammatory factors including TNF-α, interleukin (IL)-6 (IL-6), IL-8, and CXCL10 
(also known as interferon gamma-induced protein 10 or IP-10)47,108-110. These inflammatory 
factors cause excessive Ca2+ influx and oxidative stress, resulting in neuronal apoptosis.  
Notably, there is crosstalk between the extrinsic and intrinsic pathways67. For example, 
cleavage of the BCL-2-family member Bid by caspase-8 activates the mitochondrial pathway 
after apoptosis induction through death receptors, and can be used to amplify the apoptotic 
signal111. 
6. Future perspectives: Implications for therapy  
As discussed, productive infection of macrophages, neurotoxic proteins, inflammatory 
factors produced by activated non-neuronal cells, in particularly microglia cells and 
astrocytes, in the brain of HIV-1-infected individuals are involved in neuronal apoptosis in 
HIV-1 infection. Therefore, prevention or treatment of neuronal injury in HIV-1 infection 
should include strategies to combat these factors. HAART has reduced the incidence of 
severe forms of HIV-1-associated neurologic disorders such as HAD, but with longer life 
span, the prevalence of milder forms of neurologic manifestations such as HAND appears to 
be increasing. One obstacle to control brain HIV-1 infection is the fact that antiretroviral 
drugs in the HAART regimens generally have a poor penetration into the CNS112. Thus, 
novel strategies to improve the delivery of these drugs to the CNS are urgently needed. 
Studies have shown that some host factors may affect the intracellular drug concentration 
leading to the inability of drug regimens to inhibit HIV-1 replication in cells113. For example, 
the ATP-binding cassette transporter proteins, such as P-glycoprotein and multidrug 
resistance-associated proteins (MRPs), affect efflux of nucleoside reverse transcriptase 
inhibitors (NRTIs) and protease inhibitors (PIs)113. Inhibition of P-glycoprotein or MRPs 
increases uptake of saquinavir, a protease inhibitor, in the mouse brain114. Therefore, 
targeting these transporter proteins may improve delivery of HAART regimens to the CNS. 
Neurotoxic factors released from HIV-1-infected and/or activated macrophages/microglia 
play a key role in the neuronal apoptosis in HIV-1 infection. Therapies targeting activation 
of macrophages/microglia can potentially affect neuronal injury. Minocycline, a lipid soluble 
tetracycline antibiotic that has putative effects on immune system cells, has been proposed 
as a potential conjunctive therapy for HIV-1 associated neurologic disorders115. Minocycline 
has been shown to effectively cross the BBB into the CNS parenchyma to inhibit activation, 
proliferation, and viral replication of macrophages/microglia and lymphocytes in vitro116-120, 
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resulting in reduction of the production of immune activators by these cells and neurons as 
well116,121,122. In vivo studies in SIV-infected pigtailed macaques showed that minocycline 
reduced plasma virus, the pro-inflammatory monocyte chemoattractant protein 1 (MCP-
1)/CCL2, and viral DNA in the CNS115,117. The mechanisms for these effects include 
inhibition of immune cell activation, down-regulation of CD16 expression on the surface of 
monocytes, reduction of monocyte/macrophage and infected cell traffic, and suppression of 
inflammatory responses115.  
Lexipafant (an antagonist of platelet-activating factor or PAF), prinomastat (an inhibitor of 
matrix metalloprotease or MMP), inhibitors of TNF-α, and antioxidants have also been 
proposed as therapeutic drugs for HIV-1 associated neurologic disorders25. Some of these 
inhibitors of neurotoxic factors have been used to prevent or treat the pathogenesis of HAD 
and HIV-1-related neurodegeneration. One compound that has yielded interesting results is 
CPI-1189 in the treatment of HAD123. CPI-1189 ameliorates TNF-α toxicity by increasing 
activation of ERK (extracellular signal-regulated kinase)-MAP kinase124. CPI-1189 also 
attenuates toxicity of macrophage culture obtained from HAD patients in the presence of 
quinolinic acid and gp120124. However, a great deal of additional work is still necessary to 
determine the true effectiveness of any of these therapeutic inhibitors. 
Neuronal apoptosis in HIV-1 infection involves activation of NMDA receptors, alterations in 
Ca2+ homeostasis and increase of oxidative stress. MK801 (a NMDA receptor antagonist) or 
7-nitroindazole (a NOS specific inhibitor) reduces gp120-induced neuronal apoptosis in the 
neocortex of rat125. Nimodipine, a voltage-dependent Ca2+ channel antagonist, significantly 
decreased the rise in intracellular Ca2+ in neurons, but not in astrocytes123. A phase I/II trial 
of nimodipine for HIV-1-related neurologic complications was conducted and the results 
showed that nimodipine was safe and tolerated by HIV-1-infected subjects with cognitive 
impairment126. Nimodipine has been tested as an adjuvant agent to HAART to improve 
neuropsychological performance of HIV-1-infected individuals126. In addition, a trend 
toward stabilization in peripheral neuropathy was observed in nimodipine-treated 
patients126. 
Inhibitors of proapoptotic factors and caspase-3, -8 and -9 have also been tested to treat HIV-
1-associated neurologic disorders. Cultured rat cerebrocortical cells exposed to HIV-1 gp120 
undergo activation of two upstream caspases including caspase-8 and caspase-9. 
Pretreatment of these neurons with pan-caspase inhibitor (zVAD-fmk), caspase-3 peptide 
inhibitor (DEVD-fmk), caspase-8 inhibitor (IETD-fmk), or caspase-9 inhibitor (LEHD-fmk) 
prevents gp120-induced neuronal apoptosis127. Specific inhibitors of both the Fas/TNF-
α/death receptor pathway and the mitochondrial caspase pathway also prevent gp120-
induced neuronal apoptosis. These data suggest that pharmacologic interventions aimed at 
the caspase enzyme pathways may be beneficial for the prevention or treatment of HAD or 
HIV-1-associated pain. 
Our research group has recently reported that HIV-1 Tat protein directly causes 
hyperexcitability and apoptosis of DRG neurons, probably by inhibiting Cdk5 kinase 
activity and protein expression62. Tat-mediated hyperexcitability of DRG neurons may play 
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a key role in the initiation of HIV-1-associated pain in patients at the early stages of the viral 
infection. HIV-1 Tat and other proteins induce apoptosis of DRG neurons, which may be 
involved in HIV-1-associated pain at all stages of viral infection. Our findings have 
potentially important implications for developing therapeutic strategies to prevent or treat 
HIV-1-assciated pain. For example, early initiation of HAART and/or neutralization of HIV-
1 protein neurotoxicity may significantly prevent or delay HIV-1-associated pain. A recent 
study using a SIV-macaque model of HAART demonstrates that early initiation of HAART 
results in a dramatic reduction of viral RNA levels in plasma, CSF and brain128, suggesting 
that early initiation of HAART can reduce or delay neurological complications including 
pain in HIV-1-infected patients. However, pain is often under-assessed and undertreated in 
people with HIV-1/AIDS illness, and the pain etiologies that are the key for pain 
management and improvement of the quality of life have been largely unexplored. In 
addition, like cancer pain, HIV-1/AIDS-associated pain tends to be of more than one type, to 
involve more than one location, and to increase in intensity as disease progression. 
Therefore, more comprehensive studies are urgently needed to investigate the current 
global burden of pain, pain types and origins, and the spectrum of neurological injuries in 
HIV-1/AIDS patients. 
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